Drug Device Combination Products Companies

The global drug device combination products market is projected to reach USD 379.17 billion by 2030 from USD 243.02 billion in 2025, at a CAGR of 9.3% during the forecast period.

The increasing prevalence of chronic diseases, coupled with the rising geriatric population and a favorable reimbursement landscape, is expected to drive growth in the drug device combination products market over the forecast period. Additionally, enhanced government initiatives aimed at improving access to innovative drug-device combination products, along with continuous technological advancements and new product launches by major industry players, will further contribute to this expansion. However, stringent regulatory requirements may pose significant challenges for the development and adoption of these combination products among healthcare providers and patients. Furthermore, the lack of adequate training and educational resources for patients presents a notable barrier for market stakeholders.

To know about the assumptions considered for the study download the pdf brochure

Some prominent players operating in the market include Abbott (US), Boston Scientific Corporation (US), Medtronic (Ireland), Becton, Dickinson and Company (US), Novartis AG (Switzerland), Novo Nordisk A/S (Denmark), Sanofi (France), Eli, Lilly and Company (US), Merck KGaA (Germany), AbbVie Inc. (US), Teva Pharmaceutical Industries Ltd. (Israel), Stryker (US), B. Braun SE (Germany), Terumo Corporation (Japan) and Kaleo, Inc.(US).

In January 2025, Eli Lilly and Company received US FDA approval for Omvoh (mirikizumab-mrkz) to treat moderately to severely active Crohn's disease in adults.

In May 2024, Abbott launched the XIENCE Sierra Everolimus-Eluting Coronary Stent System in India. As the latest in the XIENCE family, it offers advanced safety and effectiveness for treating blocked coronary arteries, particularly in complex cases.

ABBOTT (US) is a prominent key player in the global drug device combination products market. Abbott's Medical Devices segment delivers a combination of products, particularly in high-impact areas such as cardiovascular care and diabetes management; notable innovations include drug-eluting stents and drug-coated balloons, which exemplify the company's cutting-edge approach. The company maintains a leading market position due to its extensive product portfolio and robust geographic presence across North America, Europe, and globally. With manufacturing and R&D facilities spread across over 100 countries, Abbott's products reach more than 160 countries worldwide. The company's strategy emphasizes driving innovation through substantial investments in R&D, diversifying its product offerings, and enhancing global market access. By strategically acquiring advanced technologies and focusing on enhancing its capabilities in medical devices and combination products, Abbott continues to position itself as a trailblazer in the industry.

ELI, LILLY AND COMPANY (US) is a key player and holds the second position in the global drug device combination products market. The company prioritizes R&D, maintaining a robust clinical-stage pipeline centered on biologics. It manufactures, develops, and commercializes pharmaceuticals and combination drug-device products across multiple therapeutic areas. Specifically, the company provides bespoke injection systems tailored for pharmaceutical & biotechnology firms, particularly those operating in diabetes management, growth modulation, and additional therapeutic domains. To enhance user experience in medication delivery, the company has launched innovative products. Notably, it was the pioneer in introducing the digital insulin pen, HumaPen. The organization operates across 14 countries and distributes its products in 125 countries worldwide, with a strategic emphasis on expanding its market presence in emerging economies to drive sales growth.

MEDTRONIC (Ireland) dominated the global drug device combination products market in 2024. Medtronic's predominant market position is underpinned by its extensive portfolio of combination therapies, which includes advanced medical devices such as drug-eluting stents, implantable infusion pumps, and smart insulin pens. The company boasts a robust global footprint, operating across key regions, including the US, Europe, and the Asia Pacific, and delivering solutions to clinicians, healthcare facilities, and patients in over 160 countries. R&D is a fundamental strategic pillar for Medtronic, with the company allocating approximately USD 2.84 billion to R&D in fiscal year 2024. This investment underscores the importance of innovation in maintaining and enhancing Medtronic's competitive edge, particularly in the dynamic combination products sector. Furthermore, the company actively engages in both organic growth initiatives and strategic acquisitions to reinforce its leadership and adaptability in an evolving market landscape.

Market Ranking

The global drug device combination products market is consolidated in nature, with the top players—Abbott (US), Boston Scientific Corporation (US), Medtronic (Ireland), Becton, Dickinson and Company (US), Novartis AG (Switzerland), Novo Nordisk A/S (Denmark), Sanofi (France), Eli, Lilly and Company (US), Merck KGaA (Germany), and AbbVie Inc. (US) commanding significant market shares. The competition among the leading players is high, and a majority of the players focus on establishing partnerships. The market is dominated by key players with a strong global footprint and well-established supply and distribution chains in developed regions such as North America and Europe. Smaller players strive for sustainable growth by focusing on low-price products and technological innovation, which results in a highly competitive market with numerous small and medium-sized players in developed and emerging markets. Meanwhile, the dominant market players leverage their expertise, higher R&D budgets, and strong brand recognition to minimize competition from smaller players in regional markets.

Related Reports:

Drug Device Combination Products Market by Type (Injectable, Transdermal Patch, Infusion Pump, Drug-eluting Stent, Inhaler), Application (Diabetes, Oncology, Pain, Opthamology), End User (Hospital, Home Care), and Region - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com